Prosensa Therapeutics BV and GlaxoSmithKline plc are moving forward with three additional exon-skipping antisense oligonucleotides as part of their alliance in Duchenne's muscular dystrophy (DMD).
AM-Pharma BV banked €29.2 million (US$39.8 million) in a Series D round, which, to its knowledge, is the biggest ever venture capital financing in Dutch biotechnology. The company will use the proceeds to effect a switch from a bovine to a recombinant form of alkaline phosphatase, which is in development for treatment of acute kidney injury.
In what may well be the largest Series A round in European biotechnology this year, Amakem NV raised €18 million (US$25.6 million) to fund development of a series of locally acting kinase inhibitors aimed at ophthalmology indications. (BioWorld International)
In what may well be the largest Series A round in European biotechnology this year, Amakem NV raised €18 million (US$25.6 million) to fund development of a series of locally acting kinase inhibitors aimed at ophthalmology indications.
4SC AG's histone deacetylase (HDAC) inhibitor resminostat attained the primary endpoint of a Phase II trial in patients with relapsed or refractory Hodgkin's lymphoma (HL).
Shares in Addex Pharmaceuticals AG fell more than 18 percent Monday to a 52-week low on news that Merck & Co. exited from a second partnership with the firm within weeks.
AiCuris GmbH & Co. KG gained FDA fast-track designation – and valuable mindshare – for its lead drug AIC246 (letermovir), a viral terminase inhibitor that combats human cytomegalovirus (CMV) infection. It is currently undergoing a Phase IIb trial in bone marrow transplant recipients, who are receiving the drug prophylactically, in order to prevent the dormant virus from re-emerging and causing active infection.
